SCHEMBL6866633

SCHEMBL6866633

CCCCc1nc(Cl)c(CO)n1C

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 2/20 0.44
AGTR2 P50052 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8852521 0.81 AGTR1 (0.44) AGTR1AGTR2
SCHEMBL25964231 0.81 AGTR1 (0.44) AGTR1AGTR2
SCHEMBL8297251 0.81 AGTR1 (0.36) AGTR1AGTR2
SCHEMBL13840112 0.79 AGTR1 (0.42) AGTR1AGTR2
SCHEMBL10587304 0.79 AGER (0.38) AGTR1AGTR2
SCHEMBL14546056 0.77 AGTR1 (0.31) AGTR1AGTR2
SCHEMBL14411539 0.73 AGTR1 (0.34) AGTR1AGTR2
SCHEMBL8292343 0.73 AGTR1 (0.45) AGTR1AGTR2
SCHEMBL11100306 0.73 AGTR1 (0.72) AGTR1AGTR2
SCHEMBL13841587 0.72 MPO (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023148748-A1 AN IMPROVED SAFE PROCESS FOR THE PREPARATION OF SARTAN DRUGS OF FORMULA I IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) 2023-08-10 WO disclosed
WO-2020010516-A1 DETECTION METHOD FOR N-NITROSODIMETHYLAMINE IMPURITIES 浙江华海药业股份有限公司 2020-01-16 WO disclosed
US-9492542-B2 Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2016-11-15 US disclosed
US-9492542-B2 Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2016-11-15 US disclosed
US-8569528-B2 Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides NOVARTIS AG (CH) 2013-10-29 US disclosed
US-8569528-B2 Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides NOVARTIS AG (CH) 2013-10-29 US disclosed
EP-1799639-B1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION GLENMARK PHARMACEUTICALS SA (CH) 2013-09-04 EP disclosed
US-20120330026-A1 PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES NOVARTIS AG (CH) 2012-12-27 US disclosed
US-20120330026-A1 PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES NOVARTIS AG (CH) 2012-12-27 US disclosed
US-20120220636-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F.S.P.A. (IT) 2012-08-30 US disclosed
US-20070232608-A1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2007-10-04 US disclosed
EP-1555260-B1 Phenyltetrazole compounds DIPHARMA FRANCIS SRL (IT) 2007-09-19 EP disclosed
US-20070093540-A1 PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS DIPHARMA S.P.A. (IT) 2007-04-26 US disclosed
US-20070093540-A1 PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS DIPHARMA S.P.A. (IT) 2007-04-26 US disclosed
EP-1777224-A2 A process for the preparation of angiotensin II antagonistic compounds Dipharma S.p.A. (IT) 2007-04-25 EP disclosed
US-20070043098-A1 Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides NOVARTIS PHARMACEUTICALS CORPORATION 2007-02-22 US disclosed
WO-2005020971-A1 USE OF AN ANGIOTENSIN II ANTAGONIST FOR THE PREVENTION OF MYOCARDIAL INFARCTION ASTRAZENECA AB (SE) 2005-03-10 WO disclosed
WO-2005014602-A1 PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES NOVARTIS AG (CH) 2005-02-17 WO disclosed
WO-2004087136-A1 USE OF ATII ANTAGONIST FOR THE TREATMENT OR PREVENTION OF METABOLIC SYNDROME ASTRAZENECA AB (SE) 2004-10-14 WO disclosed
US-5696116-A TREATING DISORDERS ASSOCIATED WITH VASOCONSTRICTION HOFFMANN-LA ROCHE INC. (US) 1997-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043098-A1 Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides ABL1, TBCA, TBC1D5 AGTR1 2005/4885AGTR2 1882/4885
US-20120330026-A1 PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES ABL1, TBCA, TBC1D5 AGTR1 2005/4885AGTR2 1882/4885
US-20120220636-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES ACE, ACE2, CCL11 AGTR1 6/4885AGTR2 24/4885
US-20070093540-A1 PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS AGTR2, AGTR1, ACE2 AGTR1 2/4885AGTR2 1/4885
US-20070232608-A1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM DPP4, DPP3, DPP7 AGTR1 60/4885AGTR2 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.